EW vs SNY: fair value comparison
Edwards Lifesciences Corporation and Sanofi · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EW currently sits closer to the top of our discount ranking. EW carries the stronger quality grade.
| EW | SNY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $84.37 | $44.37 |
| 12-month range | $81.26–$90.74 | $41.63–$47.40 |
| Sector rank | #45 of 113 Healthcare | #48 of 113 Healthcare |
| Quality grade | A | C |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: EW fair value analysis · SNY fair value analysis